HLX43 dose 2 trials for Non-Small-Cell Lung Cancer

All HLX43 dose 2 trials · All Non-Small-Cell Lung Cancer trials

Phase breakdown

Recruiting trials studying HLX43 dose 2 for Non-Small-Cell Lung Cancer

• A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
  NCT07253142 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
  NCT07269782 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
  NCT06848699 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations

Common questions

How many trials study HLX43 dose 2 for Non-Small-Cell Lung Cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.